Compare Kyndryl Holdings Inc (KD) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kyndryl Holdings Inc vs Sana Biotechnology Inc — how do they compare? Kyndryl Holdings Inc trades at $11.75 (market cap $2.59B), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: Kyndryl Holdings Inc is far larger — about 3.1× Sana Biotechnology Inc's market cap, and Kyndryl Holdings Inc is more actively traded (5,354,348 versus 4,507,444). Which is the better fit depends on your goals — on Pluang, investors hold Kyndryl Holdings Inc for 36 Days and Sana Biotechnology Inc for 23 Days on average.
| KD | SANA | |
|---|---|---|
Market Cap | $2.59B | $836.71M |
Volume | 5,354,348 | 4,507,444 |
Sector | Technology | Health |
52-Week High | $29.76 | $5.92 |
52-Week Low | $10.59 | $2.68 |
Typical Hold Time | 36 Days | 23 Days |
Enterprise Value | $5.41B | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kyndryl (KD) trades at $11.67, up 1.92% today, with a bearish technical signal and neutral oscillators. The company reported a return to profitability in 2025 with net income of $252 million, though revenue has declined from $18.3B in 2022 to $15.1B. Recent news highlights a strategic focus on AI, including a new innovation lab and acquisitions, aiming to drive future growth amid competitive pressures.
The outlook is mixed: positive cash flow and low EV/EBITDA suggest value, but declining revenue and modest analyst consensus ($14.67 target) indicate caution. Key risks include execution on AI initiatives and sustained top-line pressure. Institutional sentiment is neutral with 71% hold ratings, reflecting a wait-and-see approach amid transformation efforts.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
